Liberator Medical Holdings, Inc. Reports Record Revenues for Its Second Quarter Ended March 31, 2009

STUART, FL--(Marketwire - May 20, 2009) - Liberator Medical Holdings, Inc. (OTCBB: LBMH) announces net revenues of $5.83 million for the second fiscal quarter ended March 31, 2009. This represents an annual run rate of $23.3 million. Quarter-over-quarter net revenue growth was up 309% for the quarter ended March 31, 2009, compared to net revenues of $1.43 million for the quarter ended March 31, 2008. This increase was due primarily to a substantial advertising campaign to obtain new mail order customers. The Company's results reflect its restated first quarter financial statements contained in its amended Report on Form 10-Q filed May 15, 2009.

Second Quarter 2009 Highlights

--  Net revenues totaled $5.83 million for the quarter ended March 31,
    2009, up 309% from quarter ended March 31, 2008.
--  Gross profit was $3.7 million for the quarter ended March 31, 2009, up
    $2.8 million or 311% from the quarter ended March 31, 2008.
--  Operating expenses were up 127% for the quarter ended March 31, 2009,
    compared to the quarter ended March 31, 2008.
--  Net income for the quarter ended March 31, 2009, was $94,947 or $0.00
    per basic and fully diluted share.
    

Mark Libratore, Liberator Medical's CEO, stated: "We are very pleased to announce another record quarter in revenue despite its being our seasonally most difficult quarter. The period ended March 31, 2009, is historically slow due primarily to customers delaying orders until yearly insurance deductibles are met. Our revenues for the first quarter FY 2007 were $708,246 compared to $657,877 for the second quarter of FY 2007 and for the first quarter FY 2008 were $1,429,465 compared to $1,425,293 for the second quarter FY 2008. Compared to our first fiscal quarter FY 2009, our revenues increased from $5,341,840 to $5,827,234, or 9%, and our second quarter FY 2009 profit of $94,947, though less than our first quarter profit of $245,722, shows that we continue to grow as anticipated. We attribute this year's success to increased advertising, robust product offerings, diversified revenue streams and high customer retention rates."

Bob Davis, Liberator Medical's CFO, said, "Operating expenses for the second quarter of FY 2009 were 58.1% of net sales compared to operating expenses for the first quarter of FY 2009 being 56.0% of net sales. The increase in operating expenses for the second quarter was $396,796. Payroll related expenses increased by $209,158, primarily as a result of hiring additional staff for the increase in sales and filling additional key positions, such as VP of Sales, human resource manager, trainer, and computer technician. Our advertising spend was increased during the second quarter, resulting in additional advertising amortization of $160,791. Bad debt expenses increased by $130,017 as a result of increased sales and increasing our reserve for bad debt as the accounts receivable increases. General and administrative expenses decreased by $104,280."

Financial Condition

As of March 31, 2009, the Company had cash of $2,945,510, an increase of $1,772,492 from September 30, 2008. Working capital as of March 31, 2009, was $4,081,587 compared to working capital of $1,730,700 at September 30, 2008. This increase in cash was due to the Company's closing a $2.5 million convertible debt placement in October 2008. The Company only used cash of $81,967 for operating activities during the quarter. The Company incurred interest expense of $272,663 for the three months ended March 31, 2009, compared to interest of $62,131 for the three months ended March 31, 2008, an increase of $210,532, primarily due to interest expense on the issuance of convertible debt.

Results of Operations

The Company's gross profit for the three months ended March 31, 2009, was up $2,837,233, or 311%, to $3,748,949 from $911,716 for the three months ended March 31, 2008. Operating expenses for the three months ended March 31, 2009, were $3,387,149, or 58% of revenue, compared to $1,494,583, or 105% of revenue, for the three months ended March 31, 2008. The increase in operating expenses is primarily attributable to increased spending levels for employees, professional fees, advertising, and allowance for bad debts to support the increase in revenues.

The Company's net income for the three months ended March 31, 2009, increased $739,945 to $94,947 compared to a net loss of $644,998 for the three months ended March 31, 2008, due substantially to higher sales volumes at substantially lower incremental operating expense.

Stay up-to-date with current events by joining Liberator Medical's E-Mail Alert List. Join by clicking the following link: http://www.b2i.us/irpass.asp?BzID=1556&to=ea&s=0

About Liberator Medical Holdings, Inc.

Liberator Medical Holdings, Inc.'s subsidiary, Liberator Medical Supply, Inc., established the Liberator brand as a leading national direct-to-consumer provider of quality medical supplies to Medicare-eligible seniors. An Exemplary Provider™ accredited by The Compliance Team, its unique combination of marketing, industry expertise and customer service has demonstrated success over a broad spectrum of chronic conditions. Liberator is recognized for offering a simple, reliable way to purchase medical supplies needed on a regular, ongoing, repeat-order basis, with the convenience of direct billing to Medicare and private insurance. Approximately 85% of its revenue comes from supplying products to meet the rapidly growing requirements of general medical supplies, personal mobility aids, diabetes, urological, ostomy and mastectomy patients. Liberator communicates with patients and their doctors on a regular basis regarding prescriptions and supplies. Customers may purchase by phone, mail or internet, with repeat orders confirmed with the customer and shipped when needed.

Safe Harbor Statement

This release contains "forward-looking statements" made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including those related to the earnings and cash flow, leased space and number of employees. Forward-looking statements are subject to known and unknown risks and uncertainties which may cause the Company's actual results in future periods to be materially different from any future performance that may be suggested in this press release. Such risks and uncertainties may include, but are not limited to, the Company's need to raise equity capital and its ability to obtain equity financing on acceptable terms, if at all, regulatory limitations on the medical industry in general, working capital constraints, fluctuations in customer demand and commitments, fluctuation in quarterly results, introduction of new services and products, commercial acceptance and viability of new services and products, pricing and competition, reliance upon subcontractors and vendors, the timing of new technology and product introductions, the risk of early obsolescence of our products and the other factors detailed in our annual report on Form 10-KSB for the fiscal year ended September 30, 2008 and our other filings with the Securities and Exchange Commission. We assume no obligation to update the information contained in this news release.

           Liberator Medical Holdings, Inc. and Subsidiaries
                  Condensed Consolidated Balance Sheets



                                              March 31,     September 30,
                                                 2009            2008
                                            --------------- --------------
                                              (Unaudited)
                    Assets
Current Assets
Cash                                        $     2,945,510 $    1,173,018
Accounts receivable, net of allowance for
 doubtful accounts of $2,030,958 and
 $1,055,606, respectively                         3,400,620      2,405,102
Prepaid expenses                                    112,154        321,182
Inventory, net of allowance for obsolete
 inventory of $50,000 and $50,000,
 respectively                                       967,186        785,884
Deferred advertising, current portion             1,416,977        769,851
Other                                                32,723          1,848
                                            --------------- --------------
Total Current Assets                              8,875,170      5,456,885
                                            --------------- --------------


Property and Equipment
Property and Equipment, net of accumulated
 depreciation of $848,370 and $714,641,
 respectively                                       953,549        815,833

Other Assets
Deferred advertising, net of current
 portion                                          1,227,044        660,524
Deferred loan costs                                 578,339        492,821
Deposits                                            121,121        100,089
                                            --------------- --------------
Total Other Assets                                1,926,504      1,253,434
                                            --------------- --------------
Total Assets                                $    11,755,223 $    7,526,152
                                            =============== ==============


     Liabilities and Stockholders’ Equity
Current Liabilities
Accounts payable                            $     1,829,735 $      900,448
Accrued liabilities                                 386,027        289,848
Stockholder loan                                  1,664,649      1,664,649
Convertible notes payable, net of
 unamortized discount of $2,339 and
 $56,833, respectively                              794,887        772,163
Capital lease obligations, current portion           64,059         50,816
Deferred rent liability, current portion             54,226         48,261
                                            --------------- --------------
Total Current Liabilities                         4,793,583      3,726,185
                                            --------------- --------------


Long-Term Liabilities
Convertible notes payable, net of
 unamortized discount of $654,025 and
 $748,921, respectively                           5,422,670      2,788,704
Capital lease obligations, net of current
 portion                                             86,311         82,155
Deferred rent liability, net of current
 portion                                            184,683        214,215
                                            --------------- --------------
Total Long-Term Liabilities                       5,693,664      3,085,074
                                            --------------- --------------
Total Liabilities                                10,487,247      6,811,259
                                            --------------- --------------


Stockholders’ Equity
Common stock, $.001 par value, 200,000,000
 shares authorized, 32,050,366 shares
 issued, 31,987,166 and 32,050,366 shares
 outstanding at March31, 2009 and
 September30, 2008, respectively                     32,050         32,050
Additional paid-in capital                       11,419,010     11,177,266
Accumulated deficit                             (10,153,754)   (10,494,423)
                                            --------------- --------------
                                                  1,297,306        714,893
Less: Treasury stock, at cost (63,200
 shares)                                            (29,330)            --
                                            --------------- --------------
Total Stockholders’ Equity                        1,267,976        714,893
                                            --------------- --------------
Total Liabilities and Stockholders’ Equity  $    11,755,223 $    7,526,152
                                            =============== ==============




            Liberator Medical Holdings, Inc. and Subsidiaries
             Condensed Consolidated Statements of Operations
       For the three and six months ended March 31, 2009 and 2008
                              (Unaudited)


                           Three Months Ended         Six Months Ended
                                March 31,                  March 31,
                        ------------------------- ------------------------
                            2009         2008         2009         2008
                        ------------ ------------ ------------ -----------
Sales                   $  5,827,234 $  1,425,293 $ 11,169,074 $ 2,854,759

Cost of Sales              2,078,285      513,577    3,919,411   1,035,202

                        ------------ ------------ ------------ -----------

Gross Profit               3,748,949      911,716    7,249,663   1,819,557
                        ------------ ------------ ------------ -----------


Operating Expenses
Payroll, taxes and
 benefits                  1,274,261      590,062    2,339,364   1,157,547
Advertising                  458,585       77,195      756,378     144,861
Bad debts                    808,999      151,019    1,487,981     305,935
Depreciation                  67,419       45,900      133,729      91,800
General and
 administrative              777,885      630,407    1,660,050   1,230,197
                        ------------ ------------ ------------ -----------

Total Operating
 Expenses                  3,387,149    1,494,583    6,377,502   2,930,340
                        ------------ ------------ ------------ -----------


Income (Loss) from
 Operations                  361,800     (582,867)     872,161  (1,110,783)
                        ------------ ------------ ------------ -----------


Other Income (Expense)
Interest Expense            (272,663)     (62,131)    (545,175)   (113,389)
Interest Income                5,810           --       13,683          --
                        ------------ ------------ ------------ -----------

Total Other Income
 (Expense)                  (266,853)     (62,131)    (531,492)   (113,389)
                        ------------ ------------ ------------ -----------


Income (Loss) before
 Income Taxes                 94,947     (644,998)     340,669  (1,224,172)

Provision for Income
 Taxes                            --           --           --          --
                        ------------ ------------ ------------ -----------



Net Income (Loss)       $     94,947 $   (644,998) $   340,669 $(1,224,172)
                        ============ ============ ============ ===========


Basic earnings
 (loss)per share:
Weighted average shares
 outstanding              32,020,904   31,864,212   32,035,299  31,583,528
Earnings (loss)per
 share                  $       0.00 $      (0.02) $      0.01  $    (0.04)

Diluted earnings
 (loss)per share:
Weighted average shares
 outstanding              35,941,071   31,864,212   35,955,466  31,583,528
Earnings (loss)per
 share                  $       0.00 $      (0.02) $      0.01  $    (0.04)





              Liberator Medical Holdings, Inc. and Subsidiaries
               Condensed Consolidated Statements of Cash Flows
               For the six months ended March 31, 2009 and 2008
                                  (Unaudited)



                                                2009             2008
                                          ---------------- ----------------
Cash flow from operating activities:
Net Income (Loss)                         $       340,669  $    (1,224,172)

Adjustments to reconcile net loss to net
 cash used in operating activities:
Depreciation and amortization                     838,427          236,661
Equity based compensation                         271,835          269,252
Bad debt expense                                1,487,981          305,935
Non-cash interest related to convertible
 note payable                                     321,918            4,359
Amortization of loan issuance costs                20,369               --
Changes in operating assets and
 liabilities:
Accounts receivable                            (2,483,499)        (652,727)
Prepaid expenses and other current assets         (44,184)         218,169
Deposits                                          (21,032)          (2,335)
Inventory                                        (181,302)          (3,938)
Accounts payable                                  929,287          380,156
Accrued expenses                                  139,979            6,384
Deferred rent                                     (23,567)         (20,991)
Deferred loan costs                               239,496               --
Deferred advertising                           (1,918,344)        (237,031)
                                          ---------------- ----------------

Net Cash Flow Used in Operating
 Activities                                       (81,967)        (720,278)
                                          ---------------- ----------------


Cash flow from investing activities:
Purchase of property and equipment               (223,923)        (135,294)
                                          ---------------- ----------------

Net Cash Flow Used in Investing
 Activities                                      (223,923)        (135,294)
                                          ---------------- ----------------


Cash flow from financing activities:
Proceeds from sale of stock                            --          686,075
Proceeds from issuance of convertible
 notes                                          2,500,000          175,295
Broker commissions                               (203,056)              --
Legal and other fees paid                        (122,609)              --
Purchase of treasury stock                        (29,330)              --
Payments of long-term debt and capital
 lease obligations                                (66,623)         (78,391)
                                          ---------------- ----------------

Net Cash Flow Provided by Financing
 Activities                                     2,078,382          782,979
                                          ---------------- ----------------


Net (decrease)increase in cash                  1,772,492          (72,593)

Cash at beginning of period                     1,173,018          176,820
                                          ---------------- ----------------

Cash at end of period                     $     2,945,510  $       104,227
                                          ---------------- ----------------


Supplemental disclosure of cash flow
 information:
Cash paid for interest                    $       179,457  $       109,030

Supplemental schedule of non-cash
 investing and financing activities:
Capital expenditures funded by capital
 lease borrowings                         $        47,522  $            --



Contact:

Liberator Medical Holdings, Inc.
Mark Libratore
President & CEO
772-287-2414
investors@liberatormedical.com

Investor Relations Contact
Gerald Kieft or Ryan Audin
Wall Street Resources, Inc.
772-219-7525
LiberatorIR@wallstreetresources.net
http://www.wallstreetresources.net

MORE ON THIS TOPIC